Close Menu

layoffs

The firm's lab services revenues were hurt by lower sample volume, but were partially offset by a higher average price per sample. Celera also announced a restructuring program intended to cut costs by $10 million next year.

The firm, which has been unable to complete a US IPO, has cut staff, consultants, and its board of directors as it seeks funding and potential strategic alternatives.

The cost-cutting moves, which are expected to reduce Rosetta's annual operating costs by $4 million, come less than a month after the Israeli firm unveiled two new microRNA-based tests it has under development and said that it would be establishing its own sales force to market them and certain other of its next-generation products.

The firm hopes to cut its monthly burn rate 32 percent as it pushes forward with plans to launch second-generation miRview tests.

The emergence of new RNAi chemistries and technologies in recent years, and big pharma's growing interest in building up its own capabilities, suggest that Alnylam's status as the go-to partner in the field may be waning.

The firm will cut another 14 positions, on top of the previously announced 40 jobs, as it aims to reduce its operating costs.

A streamlining of its Life Sciences and Clinical Labs operations is expected to result in a reduction of annualized operating expenditures of $4 million.

The Canadian diagnostics firm aims to trim C$2 million in costs in 2011.

The firm expects to incur approximately $667,000 in restructuring costs.

The firm is pressing ahead with its plans to focus on the molecular diagnostics market. Part of its restructuring includes the departure of J. William Efcavitch as chief technology officer.

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.